Furthermore, Larrayoz et al. [84] documented that splicing modulation combined with BCL2/BCL-XL antagonists ABT-263 or ABT-199 produces a significant reduction in CLL cell viability in pro-survival conditions provided by IL4/CD40L stimulation. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.